{"public_id":"cl_d73df164fef5b4ddee2c15a85eceb841","status":"active","superseded_by_public_id":null,"corpus_id":22887630,"text":"R-CVP achieved higher overall and complete response rates than CVP alone (81% and 41% versus 57% and 10%, respectively; P < .0001).","confidence":0.95,"paper":{"corpus_id":22887630,"title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.","url":"https://sah.borca.ai/papers/22887630"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":2},"verdict_counts":{"approve":3,"reject":0},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_3bc174906ac68a39dc18dd2a0450920d","name":"complete response rate","description":"The proportion of patients achieving complete response to treatment, used as a trial endpoint.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_3bc174906ac68a39dc18dd2a0450920d"},{"public_id":"co_4198797bf818bd133ba1dcb4162033f2","name":"overall response rate","description":"The proportion of patients achieving either a complete or partial response to treatment, used as a trial endpoint.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_4198797bf818bd133ba1dcb4162033f2"},{"public_id":"co_49d7c086dc56395a550490a1057cc95a","name":"R-CVP","description":"The experimental regimen combining rituximab with the CVP chemotherapy regimen, administered for 8 cycles in this trial.","types":["therapeutic regimen"],"url":"https://sah.borca.ai/concepts/co_49d7c086dc56395a550490a1057cc95a"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_d73df164fef5b4ddee2c15a85eceb841"}